Semaglutide

The recent approval of semaglutide, a GLP-1 receptor agonist, for weight loss in China, has raised public attention. While heated discussions on semaglutide are seen in Chinese social media, limited studies have explored discourses from healthcare pr…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes. Recently, a drug targeting the receptors of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)…

Semaglutide, a medication used for type 2 diabetes and weight loss, may have unexpected side effects such as sarcopenia and age-related loss of muscle mass and strength. A 74-year-old male patient with type 2 diabetes and dyslipidemia presented with…

AIMS: Cotadutide is a dual glucagon-like peptide-1/glucagon receptor agonist. The objective of the analysis was to develop a pharmacokinetic-pharmacodynamic (PK/PD) model to describe the relationship between cotadutide exposure and response on urine…

: Patients with type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) face elevated risk of hepatobiliary complications. The biliary safety of GLP-1 and dual GLP-1/GIP receptor agonists in this population is uncertain.: We conducted a…

Obesity is one of the greatest public health concerns in the United States and has reached an epidemic scope over the past few decades. Plastic surgery in patients with obesity has been linked to higher complication rates both before and after weight…

BACKGROUND: To handle the increasing influx of prescription medication-driven weight loss (mdWL) patients in aesthetic practices, clinicians must be aligned on identifying discerning factors and strategies for managing this unique patient population.…

INTRODUCTION: Diabetes management involves using various oral hypoglycemic agents, including new glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide, tirzepatide, and liraglutide. Artificial intelligence (AI) tools such as ChatGPT (Ope…

Individuals with Duchenne muscular dystrophy (DMD) have increased risk of obesity from prolonged glucocorticoid use and progressive muscle weakness. Over 50% have obesity by the teenage years.The current study examines literature on obesity managemen…

OBJECTIVE: This study aims to systematically evaluate and perform a systematic review and network meta-analysis comparing the comprehensive cardiovascular protective effects of various glucagon-like peptide-1 receptor agonists (GLP-1RAs), focusing on…

To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs…

BACKGROUND: Conservative management of acute type A aortic dissection is challenging but may be necessary in cases of prohibitive surgical risk. CASE SUMMARY: A 33-year-old man with acute type A aortic dissection was ineligible for surgery owing to s…

BACKGROUND: Glucagon-like peptide-1 receptor agonists and their analogues have emerged as effective pharmacotherapies for obesity. OBJECTIVE: To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, liraglutide, and oral…

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has transformed the treatment landscape for type 2 diabetes and obesity due to its robust efficacy and wide-ranging therapeutic benefits. This review outlines semaglutide's diverse me…

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been increasingly used for the management of type II diabetes mellitus (T2DM). Although recent literature suggests semaglutide may reduce postoperative total knee arthroplasty (…

BACKGROUND: Intrauterine adhesions (IUA) seriously affect female reproductive function, but the clinical treatment effect is not good. Semaglutide and Dulaglutide, receptor agonists of the gastrointestinal hormone GLP-1, have been reported to allevia…